Sophiris Bio IncTSX: SHS

Sophiris Bio Reports First Quarter Financial Results and Achievements

· Issued by Sophiris Bio Inc via CNW

SAN DIEGO AND VANCOUVER, May 14, 2012 /CNW/ - Sophiris Bio Inc. (Sophiris, TSX: SHS), a developer of innovative products for the treatment of urological diseases, today announced financial results and achievements for the first quarter ended March 31, 2012.

"We are pleased with our progress during the quarter. On March 28th, we announced the completion of dosing of all four cohorts in our Transrectal Study of PRX302 for the treatment of benign prostatic hyperplasia (BPH) and we look forward to releasing our three month safety results from the study in the Third Quarter of this year," said Dr. Lars Ekman, Executive Chairman and President of Sophiris. Dr. Ekman added, "We also strengthened our cash position in the Quarter by completing a follow-on financing with our largest shareholder Warburg Pincus providing meaningful additional resources to drive the continued advancement of PRX302 for the treatment of BPH."

Key Operational and Financial Highlights

  • Completion of dosing of all four cohorts of patients in our Transrectal Study of PRX302 for the treatment of BPH.
  • Closed an additional CND $8.3 million investment from our largest shareholder, Warburg Pincus pursuant to its rights under the terms of the existing Investment Agreement dated September 28, 2010.

Quarter Ended March 31, 2012

The Company reported a net loss of $4.5 million ($0.03 per share) for the three months ended March 31, 2012, compared to a net loss of $2.2 million ($0.02 per share) for the three months ended March 31, 2011, representing an increase of $2.3 million. The increase in net loss was driven primarily from an increase in total expenses of $1.9 million over the same period as a result of our increased research and development activities associated with our on-going Transrectal Study and PRX302 clinical material manufacturing expenses.

Research and Development Costs

Research and development costs were $3.1 million for the three months ended March 31, 2012, versus $1.3 million for the three months ended March 31, 2011, an increase of $1.8 million. The increase in research and development expenses is primarily attributable to the ongoing Transrectal study of PRX302 and the Chemistry, Manufacturing and Controls (CMC) program for PRX302 clinical material supply.

General and Administrative Costs

General and administrative costs for the three months ended March 31, 2012, were $1.0 million, an increase of $0.1 million from the $0.9 million incurred during the three months ended March 31, 2011. The increase is due primarily due to expenses associated with our recent name change and personnel related costs partially offset by a reduction in legal and consulting expenses.

Interest Income

Interest income remained fairly consistent at $12,000 for the three months ended March 31, 2012 compared to $13,000 for the three months ended March 31, 2011.

Interest Expense

During the three months ended March 31, 2012, the Company incurred interest expense related to the Company's secured promissory note with Oxford Financial LLC of $0.5 million. The secured promissory note was originated during July 2011 as such there is no interest expense related to this loan during the three months ended March 31, 2011.

For complete financial results, please see our filings at www.sedar.com.

About Sophiris

Sophiris is a developer of innovative products for the treatment of urological diseases. Sophiris' lead program, PRX302 (PORxin), achieved positive results from its Phase 2b placebo controlled trial called TRIUMPH, to treat benign prostatic hyperplasia (BPH or enlarged prostate). Sophiris has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. For more information, please visit www.sophirisbio.com.

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris' current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Sophiris Bio Inc.
Condensed Consolidated Statement of Operations, Comprehensive Loss and Deficit
(Stated in United States Dollars - Unaudited)
For the three months ended March 31,
20122011
$$
Expenses
Research and development3,091,1751,336,369
General and administrative1,005,825888,417
4,097,0002,224,786
Other income (expense)
Interest income12,35013,150
Interest expense(518,603)-
Foreign exchange gain (loss)74,243(22,830)
(432,010)(9,680)
Net loss for the period(4,529,010)(2,234,466)
Other comprehensive income
Currency translation differences153,943260,973
Total comprehensive loss for the period(4,375,067)(1,973,493)
Deficit - Beginning of the period(52,513,353)(38,302,696)
Deficit - End of the period(57,042,363)(40,537,162)
Basic and diluted loss per share(0.03)(0.02)
Weighted average number of outstanding shares-
Basic and diluted143,646,663121,332,748
Sophiris Bio Inc.
Condensed Consolidated Statement of Financial Position
(Stated in United States Dollars - Unaudited)
March 31,December 31,
20122011
$$
Assets
Current assets
Cash and cash equivalents26,906,41223,410,478
Other receivables169,877238,906
Prepaid expenses313,448284,770
27,389,73723,934,154
Non-current assets
Property and equipment209,453219,740
Intangible assets272,319316,099
Other long term assets35,75329,495
Total assets27,907,26224,499,488
Liabilities
Current liabilities
Accounts payable and accrued liabilities2,252,0043,101,548
Current portion of secured promissory notes4,611,30714,456,768
6,863,31117,558,316
Long-term portion of secured promissory notes10,007,813-
Shareholders' equity
Common shares54,490,66748,073,120
Common share purchase warrants7,794,4775,926,762
Contributed Surplus7,620,6337,435,862
Currency translation differences(1,827,276)(1,981,219)
Deficit(57,042,363)(52,513,353)
Total shareholders' equity11,036,1386,941,172
Total liabilities and shareholders' equity27,907,26224,499,488
Sophiris Bio Inc.
Condensed Consolidated Statement of Cash Flows
(Stated in United States Dollars - Unaudited)
For the three months ended March 31,
20122011
$$
Cash flows used in operating activities
Net loss for the period(4,529,010)(2,234,466)
Items not affecting cash:
Stock-based compensation184,771386,585
Accretion expense162,349-
Depreciation of property and equipment19,7014,238
Amortization of intangible assets49,77750,563
Unrealized foreign exchange loss456,449341,636
Interest expense356,254-
Interest income(12,350)(13,150)
Change in non-cash working capital:
Other receivables73,41115,753
Prepaid expenses(28,474)(11,653)
Other long-term assets(6,118)-
Accounts payable and accrued liabilities(1,016,236)145,324
Net cash flows used in operating activities(4,289,468)(1,215,170)
Cash flows used in investing activities
Interest received12,35013,150
Purchase of property and equipment(9,389)(6,070)
Net cash from investing activities2,9617,080
Cash flows from financing activities
Issuance of common shares from private placement
- net of issurance costs paid8,343,738-
Issuance of common shares on exercise of warrants-14,954
Interest paid(356,254)-
Net cash from financing activities7,987,48414,954
Effect of exchange rate changes on cash
and cash equivalents(205,043)(64,793)
Net increase (decrease) in cash and cash equivalents3,495,934(1,257,929)
Cash and cash equivalents - Beginning of the period23,410,47812,381,237
Cash and cash equivalents - End of the period26,906,41211,123,308

Lauren Glaser
Investor Relations
The Trout Group
646-378-2972
lglaser@troutgroup.com

James Beesley
Investor Relations
Sequoia Partners
778-389-7715
james@sequoiapartners.ca

Michael Moore
Investor Relations
Equicom Group
619-467-7067
mmoore@equicomgroup.com

Sophiris Bio Inc on 6ix

Earlier from Sophiris Bio

Later from Sophiris Bio

All Sophiris Bio news releases